DAEWOONG PHARMACEUTICAL INDIA PRIVATE LIMITED

Company Introduction

DAEWOONG PHARMACEUTICAL INDIA PRIVATE LIMITED is the Indian subsidiary of Daewoong Pharmaceutical Co., Ltd., a prominent global healthcare group headquartered in South Korea. Established to strengthen Daewoong's footprint in the Indian pharmaceutical market, the company is primarily engaged in the marketing, sales, and distribution of a wide array of pharmaceutical products. These products encompass various therapeutic areas and include innovative solutions developed by its parent company, such as specialty drugs and aesthetic products. The company aims to provide high-quality and effective medicines to patients and healthcare providers across India, leveraging the parent company's robust research and development capabilities and global expertise. Its operations are focused on market penetration, brand building, and establishing a strong commercial presence in one of the world's fastest-growing pharmaceutical markets.

Factory or Trader

DAEWOONG PHARMACEUTICAL INDIA PRIVATE LIMITED primarily functions as a commercial entity, acting as a trader and distributor of pharmaceutical products in India. It is not primarily a manufacturing factory. Its main activities involve the marketing, sales, and distribution of products manufactured by its parent company, Daewoong Pharmaceutical Co., Ltd., and potentially through local contract manufacturing arrangements.

DAEWOONG PHARMACEUTICAL INDIA PRIVATE LIMITED manufactures or sells a range of pharmaceutical products primarily sourced from its parent company, Daewoong Pharmaceutical Co., Ltd. of South Korea. These products generally fall into several key therapeutic areas. The company offers gastrointestinal drugs, including those for conditions like GERD such as Fexuprazan, and liver support medications like Ursodeoxycholic Acid. They also market biologics and aesthetic products, most notably Nabota, which is a botulinum toxin formulation. Furthermore, their portfolio includes products for metabolic and endocrine disorders, cardiovascular conditions, and central nervous system disorders. Other ethical pharmaceuticals covering various therapeutic segments are also part of their offerings, subject to regulatory approvals in India.